Catalyst Biosciences to Present at the Cowen Healthcare Conference
To access a live webcast of the presentation, please visit http://wsw.com/webcast/cowen57/cbio/.
An archived webcast of the presentation will be available for 90 days on the Events and Presentations section on the Company’s website.
Catalyst is a clinical-stage biopharmaceutical company focused on addressing unmet needs in rare diseases and systemic complement mediated disorders. Our protease engineering platform includes development programs in hemophilia and a research program on subcutaneous (SQ) systemic complement inhibitors. Our engineered coagulation factors are designed to overcome the significant limitations of current IV treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Our lead asset, MarzAA (FVIIa) has successfully completed Phase 2 development, reducing the annualized bleed rate (ABR) in individuals with hemophilia A or B with inhibitors by >90%. Our second hemophilia asset, DalcA (FIX) is completing a Phase 2b clinical trial for the prophylactic treatment of hemophilia B and has achieved FIX levels from 12-27%. We also have a global license and collaboration agreement with Biogen for the development and commercialization of pegylated CB 2782 (anti-C3 protease) for the potential treatment of geographic atrophy associated dry age-related macular degeneration.
For more information, please visit www.catalystbiosciences.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential uses and benefits of Catalyst’s products in development to address hemophilia indications and other rare bleeding disorders, including the potential benefits of SQ dosing and about Catalyst’s collaboration with Biogen. Actual results or events could differ materially from the expectations disclosed in the forward-looking statements as a result of various important factors, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of MarzAA or DalcA, including the generation of antibodies, which has been observed in patients treated with DalcA, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, the risk that Biogen will terminate the collaboration, competition and other factors that affect our ability to establish collaborations on commercially reasonable terms and other risks described in the “Risk Factors” section of the Company’s annual report filed with the
Source: Catalyst Biosciences, Inc.